| Id |
Subject |
Object |
Predicate |
Lexical cue |
| T1 |
0-117 |
Sentence |
denotes |
Outcomes of high-dose chemotherapy and autologous stem-cell transplantation in stage IIIB inflammatory breast cancer. |
| T2 |
118-126 |
Sentence |
denotes |
PURPOSE: |
| T3 |
127-429 |
Sentence |
denotes |
To evaluate the disease-free survival (DFS) and overall survival (OS), prognostic factors, and treatment-related mortality of women with stage IIIB inflammatory breast cancer (IBC) treated with combined modality therapy (CMT) and high-dose chemotherapy (HDCT) with autologous stem-cell transplantation. |
| T4 |
430-451 |
Sentence |
denotes |
PATIENTS AND METHODS: |
| T5 |
452-602 |
Sentence |
denotes |
Between 1989 and 1997, 47 consecutive patients with stage IIIB IBC were treated with CMT and HDCT and were the subject of this retrospective analysis. |
| T6 |
603-688 |
Sentence |
denotes |
Chemotherapy was administered to all patients before and/or after definitive surgery. |
| T7 |
689-811 |
Sentence |
denotes |
Neoadjuvant and adjuvant chemotherapy was administered to 33 and 34 patients, respectively, and 20 patients received both. |
| T8 |
812-938 |
Sentence |
denotes |
All patients received HDCT with autologous stem-cell transplantation, and 41 patients received locoregional radiation therapy. |
| T9 |
939-1020 |
Sentence |
denotes |
Tamoxifen was prescribed to patients with estrogen receptor (ER)-positive cancer. |
| T10 |
1021-1029 |
Sentence |
denotes |
RESULTS: |
| T11 |
1030-1168 |
Sentence |
denotes |
The mean duration of follow-up from diagnosis was 30 months (range, 6 to 91 months) and from HDCT was 22 months (range, 0.5 to 82 months). |
| T12 |
1169-1274 |
Sentence |
denotes |
At 30 months, the Kaplan-Meier estimates of DFS and OS from diagnosis were 57.7% and 59.1%, respectively. |
| T13 |
1275-1378 |
Sentence |
denotes |
At 4 years, the Kaplan-Meier estimates of DFS and OS from diagnosis were 51.3% and 51.7%, respectively. |
| T14 |
1379-1651 |
Sentence |
denotes |
In a multivariate analysis, the only factors associated with better survival were favorable response to neoadjuvant chemotherapy (P =.04) and receipt of tamoxifen (P =.06); however, the benefit of tamoxifen was only demonstrated in patients with ER-positive breast cancer. |
| T15 |
1652-1687 |
Sentence |
denotes |
At last follow-up, 28 patients (59. |
| T16 |
1688-1720 |
Sentence |
denotes |
6%) were alive and disease-free. |
| T17 |
1721-1782 |
Sentence |
denotes |
Seventeen patients (36.2%) developed recurrent breast cancer. |
| T18 |
1783-1807 |
Sentence |
denotes |
Seventeen patients died: |
| T19 |
1808-1895 |
Sentence |
denotes |
15 from disease recurrence and two (4.2%) from treatment-related mortality due to HDCT. |
| T20 |
1896-1907 |
Sentence |
denotes |
CONCLUSION: |
| T21 |
1908-2066 |
Sentence |
denotes |
In this analysis, the early results of treatment with CMT and HDCT compare favorably with other series of patients with stage IIIB IBC treated with CMT alone. |
| T22 |
2067-2145 |
Sentence |
denotes |
These outcomes must be confirmed with longer follow-up and controlled studies. |
| T1 |
0-117 |
Sentence |
denotes |
Outcomes of high-dose chemotherapy and autologous stem-cell transplantation in stage IIIB inflammatory breast cancer. |
| T2 |
118-126 |
Sentence |
denotes |
PURPOSE: |
| T3 |
127-429 |
Sentence |
denotes |
To evaluate the disease-free survival (DFS) and overall survival (OS), prognostic factors, and treatment-related mortality of women with stage IIIB inflammatory breast cancer (IBC) treated with combined modality therapy (CMT) and high-dose chemotherapy (HDCT) with autologous stem-cell transplantation. |
| T4 |
430-451 |
Sentence |
denotes |
PATIENTS AND METHODS: |
| T5 |
452-602 |
Sentence |
denotes |
Between 1989 and 1997, 47 consecutive patients with stage IIIB IBC were treated with CMT and HDCT and were the subject of this retrospective analysis. |
| T6 |
603-688 |
Sentence |
denotes |
Chemotherapy was administered to all patients before and/or after definitive surgery. |
| T7 |
689-811 |
Sentence |
denotes |
Neoadjuvant and adjuvant chemotherapy was administered to 33 and 34 patients, respectively, and 20 patients received both. |
| T8 |
812-938 |
Sentence |
denotes |
All patients received HDCT with autologous stem-cell transplantation, and 41 patients received locoregional radiation therapy. |
| T9 |
939-1020 |
Sentence |
denotes |
Tamoxifen was prescribed to patients with estrogen receptor (ER)-positive cancer. |
| T10 |
1021-1029 |
Sentence |
denotes |
RESULTS: |
| T11 |
1030-1168 |
Sentence |
denotes |
The mean duration of follow-up from diagnosis was 30 months (range, 6 to 91 months) and from HDCT was 22 months (range, 0.5 to 82 months). |
| T12 |
1169-1274 |
Sentence |
denotes |
At 30 months, the Kaplan-Meier estimates of DFS and OS from diagnosis were 57.7% and 59.1%, respectively. |
| T13 |
1275-1378 |
Sentence |
denotes |
At 4 years, the Kaplan-Meier estimates of DFS and OS from diagnosis were 51.3% and 51.7%, respectively. |
| T14 |
1379-1651 |
Sentence |
denotes |
In a multivariate analysis, the only factors associated with better survival were favorable response to neoadjuvant chemotherapy (P =.04) and receipt of tamoxifen (P =.06); however, the benefit of tamoxifen was only demonstrated in patients with ER-positive breast cancer. |
| T15 |
1652-1687 |
Sentence |
denotes |
At last follow-up, 28 patients (59. |
| T16 |
1688-1720 |
Sentence |
denotes |
6%) were alive and disease-free. |
| T17 |
1721-1782 |
Sentence |
denotes |
Seventeen patients (36.2%) developed recurrent breast cancer. |
| T18 |
1783-1807 |
Sentence |
denotes |
Seventeen patients died: |
| T19 |
1808-1895 |
Sentence |
denotes |
15 from disease recurrence and two (4.2%) from treatment-related mortality due to HDCT. |
| T20 |
1896-1907 |
Sentence |
denotes |
CONCLUSION: |
| T21 |
1908-2066 |
Sentence |
denotes |
In this analysis, the early results of treatment with CMT and HDCT compare favorably with other series of patients with stage IIIB IBC treated with CMT alone. |
| T22 |
2067-2145 |
Sentence |
denotes |
These outcomes must be confirmed with longer follow-up and controlled studies. |